The purpose of the present study was to determine the diagnostic utility of selected MMPs, MMP-2, MMP-3, MMP-11 and MMP-26, as new biomarkers in patients with ovarian cancer and to compare the results obtained with routinely determined markers CA125 and HE4 and the ROMA algorithm. This evidence concerns the gene WFDC2 and ovarian cancer.